CSIMarket Company Name, Ticker, Competitors, else..
 
Akili Inc   (AKLI)
Other Ticker:  
 
 
Price: $0.4320 $0.00 -0.621%
Day's High: $0.449 Week Perf: -0.62 %
Day's Low: $ 0.43 30 Day Perf: 2.88 %
Volume (M): 236 52 Wk High: $ 0.74
Volume (M$): $ 102 52 Wk Avg: $0.35
Open: $0.43 52 Wk Low: $0.19



 Market Capitalization (Millions $) 34
 Shares Outstanding (Millions) 79
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 0

Akili Inc
Akili Inc is a digital medicine company that is focused on developing clinically-validated prescription treatments using video game technology. They create interactive entertainment experiences designed to target specific cognitive systems in the brain. These digital therapies are aimed at addressing various medical conditions and improving neurological conditions. Akili's products have been successfully used in clinical trials and show potential in treating conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The company is at the forefront of the emerging field of digital therapeutics, utilizing innovative technology to provide novel treatment options.


   Company Address: 71 Commercial Street Boston 2109 MA
   Company Phone Number: 313-8853   Stock Exchange / Ticker: NASDAQ AKLI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
LFST        3.74% 
PIII        15.9% 
MNMD        7.85% 
TDOC        26.33% 
• View Complete Report
   



Business Update

Digital Game-Changer FDA Approves Akilis EndeavorOTC as Revolutionary Over-the-Counter Treatment for Adult ADHD

Published Wed, Jun 19 2024 4:52 AM UTC

In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has granted clearance to Akili, Inc. for their digital therapeutic, EndeavorOTC (AKL-T01), marking a significant development in the treatment of attention-deficit/hyperactivity disorder (ADHD) among adults. This clearance highlights the increasing recognition and adoption of digital interventions as potent...
Business Update

Empowering Adults with ADHD The Game-Changer in Mental Health Treatment

Published Tue, Jun 18 2024 9:08 PM UTC

The Future of ADHD Treatment: Akili Announces FDA Clearance for Over-the-Counter Digital TherapyIn a groundbreaking development for the field of mental health, Akili Inc. has received FDA authorization for the first over-the-counter digital treatment for adults with attention-deficit/hyperactivity disorder (ADHD). The clearance of EndeavorOTC (AKL-T01) marks a significant mi...
Business Update

Akili Inc. Initiates Evaluation of Strategic Alternatives to Enhance Shareholder Value

Published Tue, May 14 2024 8:47 PM UTC

Boston-based digital medicine company, Akili Inc. (Nasdaq: AKLI), released its financial results for the first quarter ended March 31, 2024, along with an update on its business progress. In a recent announcement made in late April 2024, the company's board of directors has initiated a comprehensive evaluation of potential strategic alternatives to enhance shareholder value....
Business Update

Akili Announces Strategic Amendments with Shionogi and Shows Promise with Sequential Revenue Growth

Published Tue, Apr 30 2024 12:47 PM UTC

Leading digital medicine company, Akili Inc., recently announced several corporate updates, underscoring its evolving distribution agreement with pharmaceutical giant Shionogi & Co., Ltd. This amendment sees the cancellation of a significant long-term debt obligation and additional payments for the Japanese version of Akili's flagship product, AKL-T01. Alongside these develo...
Akili Inc

Despite revenue surge, Medical Equipment & Supplies Company struggles to achieve profitability at Akili Inc in Q3 2023

Akili Inc, a medical equipment and supplies company, announced a remarkable increase in revenue for the third quarter of 2023. Their revenue surged by 756.098% year on year to $0.70 million, outperforming their industry peers who achieved an average top-line growth of 4.89% in the same period. This improvement in revenue also represents a significant advancement from the preceding quarter, where Akili Inc experienced a shortfall of $-0.15 per share and doubled their revenue by 515.789% to $0.11 million.
However, despite the positive revenue growth, Akili Inc recorded a shortfall per stock of $-0.20. This shortfall indicates that the company's expenses exceeded their revenue during the mentioned period.






Akili Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com